The breadth of the market favoured the advances with 764 stocks advancing and 913 declining while 384 remained unchanged. On the BSE, 1157 stocks advanced, 1297 declined and 142 remained unchanged.
The latest lawsuit is a part of growing litigation against the makers and distributors of sartan-based blood pressure lowering drugs in the US, the report said.
In coming week any tick above 9,350 on Nifty Pharma index will trigger fresh buying in pharma stocks, Arpan Shah of Monarch Networth Capital said
A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company
The slowdown in production at Morgantown site could provide a window of opportunity to Mylan's peers
The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation.
HDFC Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 875 in its research report dated November 14, 2018.
Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated November 13, 2018.
Aurobindo Pharma has said it's wholly-owned subsidiaryhas entered into an agreement to acquire a product under development and related assets from Australia-based Advent Pharmaceuticals Pty Ltd for USD 12.5 million.
The earnings before interest, taxes, depreciation and amortization was reported at Rs 986.3 crore for the September quarter.
Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.
Trends on SGX Nifty indicate a positive opening for the broader index in India, a gain of 70.5 points or 0.69 percent. Nifty futures were trading around 11,299-level on the Singaporean Exchange.
Sector-wise, FMCG, IT and Pharma could see a weak trend. Here's Swait Hotkar, Technical Analyst at Nirmal Bang, recommending what to pick in this episode of Buy or Sell.
We expect Nifty to continue within a broader range of 10,100-10,700 in the near future and either side decisive breakout would trigger the next directional move.
Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.
Net Sales are expected to increase by 4.6 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 4,638.9 crore, according to ICICI Direct.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Azithromycin oral suspension 100 mg /5 mL and 200 mg/5 mL, Aurobindo Pharma said in a statement.
In our latest episode of Buy or Sell, Sameet Chavan, Chief Analyst at Angel Broking suggest specific stocks likely to yield high returns, such as Aurobindo Pharma among others.
Trends on SGX Nifty indicate a negative opening for the broader index in India, a plunge of 240 points or 2.29 percent. Nifty futures were trading around 10,240-level on the Singaporean Exchange.
Indian markets are in the midst of a correction which is likely to extend further, according to experts and hence, there will be plenty of opportunities for investors to enter into quality stocks on declines
The Hyderabad-based drug firm said it has received approval from the South African Health Products Regulatory Authority (SAHPRA) and is now among the first few companies which have received nod for this product.
Aurobindo is now among the first few companies which has received approval for this product.